Business
ARIUS Receives Six Key US Patents
ARIUS Receives Six Key US Patents.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\n\nStrengthens Intellectual Property Portfolio on Lead Programs and Antibody\nAssets\n\nTORONTO, Nov. 28 /CNW/ - ARIUS Research Inc. (\"ARIUS\" or the \"Company\")\n(TSX: ARI) announced today that it has received Notices of Allowance from the\nUnited States Patent and Trademark Office for patents on their lead antibody,\nARH460-16-2, targeting the CD44 antigen implicated as markers of cancer stem\ncells in breast and prostate cancer plus separate patents covering antibodies\nto the CD63, CD59 and MCSP antigens.\nThese patents are important additions to the ARIUS Intellectual Property\nportfolio that underlie the value of existing partnerships and ongoing\nbusiness development and licensing activities. ARIUS has licensing and\ncollaboration agreements with leading biotechnology and pharmaceutical\ncompanies such as Genentech, Takeda and PDL Biopharma with a global potential\nvalue to ARIUS of approximately $400 million plus royalties on sales. ARIUS\nwill be eligible for these milestone fees based on research activities,\nclinical milestones, regulatory approvals and 1st commercial sales. The terms\ninclude $10.7 million in upfront payments, equity investment and research\nsupport funding.\nThese new patents cover the antibody molecules and various uses of each\nantibody and other similar antibodies to treat cancers such as ovarian,\nprostate and breast cancer. In addition, ARIUS has patent claims covering\nepitopes or specific parts of a cancer antigen target. This patent approach\nrepresents a large step up in value over more general target coverage because\nit is the epitope that determines what a cell will do when an antibody binds\nto it. In ARIUS' case, functional antibodies bind to epitopes that signal a\ncancer cell to die.\nARIUS has over 80 additional patents pending that will continue to\nenhance the value of the Company and the strength of upcoming deals. The\nCompany actively applies for patents on additional technology, products, and\nuses of products on an ongoing basis.\n\"Patents are crucial to being able to extract the value from the work\nthat we do and are one of the main reasons we are an attractive partner for\nboth large pharmaceutical and biotechnology companies,\" said Dr. David S.\nYoung, President and Chief Executive Officer of ARIUS. \"Some of these current\npatents represent a novel approach to...